A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis

Drugs Exp Clin Res. 1990;16(1):29-37.

Abstract

A 12-week trial was carried out to compare the efficacy of pirazolac (300-600 mg b.i.d.) with that of indomethacin (25-50 mg t.i.d.) in patients with ankylosing spondylitis. A total of 119 patients completed the treatment period, with 32 drop-outs. Both therapies showed significant improvements in clinical symptoms.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Tolerance
  • Female
  • Humans
  • Indomethacin / administration & dosage
  • Indomethacin / adverse effects
  • Indomethacin / therapeutic use*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Spondylitis, Ankylosing / drug therapy*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Pyrazoles
  • pirazolac
  • Indomethacin